Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14866116 | 0.95 | PAM (0.34) | PAM | |
| SCHEMBL4261273 | 0.87 | PAM (0.42) | PAMTP53 | |
| SCHEMBL13949509 | 0.86 | — | — | |
| SCHEMBL18162008 | 0.85 | PAM (0.41) | PAM | |
| SCHEMBL15504792 | 0.84 | — | — | |
| SCHEMBL13949506 | 0.79 | — | — | |
| SCHEMBL41709 | 0.78 | TP53 (0.43) | PAMTP53 | |
| SCHEMBL27483337 | 0.78 | TP53 (0.43) | PAMTP53 | |
| SCHEMBL18159124 | 0.78 | NAAA (0.49) | PAM | |
| SCHEMBL17368711 | 0.78 | NAAA (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170354592-A1 | PARENTERAL SUSTAINED-RELEASE DELIVERY OF CARVEDILOL DISPERSE SYSTEMS | ASCENDIA PHARMACEUTICALS, LLC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20140377369-A2 | COMPOSITIONS OF ROTIGOTINE, DERIVATIVES THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS OF ROTIGOTINE OR ITS DERIVATIVES | GENEORA PHARMA (SHIJIAZHUANG) CO., LTD. (CN) | 2014-12-25 | — | — | US | disclosed |
| US-20130309314-A1 | COMPOSITIONS OF ROTIGOTINE, DERIVATIVES THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS OF ROTIGOTINE OR ITS DERIVATIVE | LI YOUXIN (DE) | 2013-11-21 | — | — | US | disclosed |
| US-8481558-B2 | Compounds to inhibit or augment an inflammatory response | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| US-8067022-B2 | Inhibiting stenosis following vascular trauma or disease by administering a conjugate of a vascular smooth muscle binding protein that associates with a cell surface of the vascular smooth muscle coupled to a drug inhibiting cellular activity | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-7989466-B2 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-20090196931-A1 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | KUNZ LAWRENCE L | 2009-08-06 | — | — | US | disclosed |
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. | 2008-02-21 | — | — | US | disclosed |
| US-7238711-B1 | Compounds and methods to inhibit or augment an inflammatory response | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2007-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309314-A1 | COMPOSITIONS OF ROTIGOTINE, DERIVATIVES THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS OF ROTIGOTINE OR ITS DERIVATIVE | PARK7, PRLHR, PRPH | PAM 2907/4885TP53 4538/4885 |
| US-20090196931-A1 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | MYLK, TNNI3, MYLK2 | PAM 3818/4885TP53 4453/4885 |
| US-20140377369-A2 | COMPOSITIONS OF ROTIGOTINE, DERIVATIVES THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS OF ROTIGOTINE OR ITS DERIVATIVES | PARK7, PRLHR, ADCYAP1R1 | PAM 2997/4885TP53 4638/4885 |
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CCL2, CCL11, CCL5 | PAM 3543/4885TP53 2268/4885 |
| US-20170354592-A1 | PARENTERAL SUSTAINED-RELEASE DELIVERY OF CARVEDILOL DISPERSE SYSTEMS | NPC1L1, PNLIP, LIPA | PAM 4254/4885TP53 4672/4885 |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CCL2, CCL5, CCL11 | PAM 3306/4885TP53 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.